Nasdaq100 ETF vs uniQure N.V. Ordinary Shares — how do they compare? Nasdaq100 ETF trades at $721.28 (market cap $501.32B), while uniQure N.V. Ordinary Shares trades at $20.78 (market cap $1.48B). The key difference: Nasdaq100 ETF is far larger — about 338.7× uniQure N.V. Ordinary Shares's market cap, and Nasdaq100 ETF is trading nearer its 52-week high, uniQure N.V. Ordinary Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Nasdaq100 ETF for 163 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| QQQ | QURE | |
|---|---|---|
Market Cap | $501.32B | $1.48B |
Volume | 28,524,918 | 2,488,780 |
52-Week High | $759.66 | $70.59 |
52-Week Low | $558.34 | $9.03 |
Typical Hold Time | 163 Days | 0 Days |
Sector | — | Health |
Enterprise Value | — | $728.62M |
Signals from Pluang's Aura AI — not financial advice
QQQ trades at $728.95, down 2.28% today amid broader market pressure. Technical indicators show a bullish trend with moving averages supporting upside momentum, while oscillators remain neutral. The ETF faces mixed analyst sentiment with a 50/50 split between buy and sell recommendations. Recent news highlights concerns about AI market sustainability and Fed rate impacts, though historical patterns suggest potential post-midterm election strength.
QQQ's concentrated tech exposure offers growth potential through AI-driven innovation but carries valuation risks amid elevated market levels. Key risks include interest rate sensitivity and sector concentration, while institutional expansion through new international ETFs signals long-term confidence in the innovation theme.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
The ETF is designed to track the performance of the securities and the stocks in the NASDAQ-100 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on QQQ →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →